CA3116198A1 - Compounds containing deuterium - Google Patents
Compounds containing deuterium Download PDFInfo
- Publication number
- CA3116198A1 CA3116198A1 CA3116198A CA3116198A CA3116198A1 CA 3116198 A1 CA3116198 A1 CA 3116198A1 CA 3116198 A CA3116198 A CA 3116198A CA 3116198 A CA3116198 A CA 3116198A CA 3116198 A1 CA3116198 A1 CA 3116198A1
- Authority
- CA
- Canada
- Prior art keywords
- melflufen
- deuterium
- compound
- mol
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816998.7 | 2018-10-18 | ||
| GBGB1816998.7A GB201816998D0 (en) | 2018-10-18 | 2018-10-18 | Compounds |
| GB1909695.7 | 2019-07-05 | ||
| GBGB1909695.7A GB201909695D0 (en) | 2019-07-05 | 2019-07-05 | Compounds |
| PCT/EP2019/078250 WO2020079165A1 (en) | 2018-10-18 | 2019-10-17 | Compounds containing deuterium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3116198A1 true CA3116198A1 (en) | 2020-04-23 |
Family
ID=68290247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3116198A Pending CA3116198A1 (en) | 2018-10-18 | 2019-10-17 | Compounds containing deuterium |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12152087B2 (https=) |
| EP (1) | EP3866931B1 (https=) |
| JP (2) | JP7603199B2 (https=) |
| KR (1) | KR102848971B1 (https=) |
| CN (1) | CN112930214B (https=) |
| AU (1) | AU2019362389B2 (https=) |
| BR (1) | BR112021007060A2 (https=) |
| CA (1) | CA3116198A1 (https=) |
| DK (1) | DK3866931T3 (https=) |
| ES (1) | ES2942468T3 (https=) |
| FI (1) | FI3866931T3 (https=) |
| HU (1) | HUE061801T2 (https=) |
| IL (1) | IL282231B2 (https=) |
| MA (1) | MA53904A (https=) |
| MX (1) | MX2021004474A (https=) |
| PL (1) | PL3866931T3 (https=) |
| SG (1) | SG11202103726RA (https=) |
| WO (1) | WO2020079165A1 (https=) |
| ZA (1) | ZA202102492B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| EP4347615B1 (en) * | 2021-06-01 | 2025-05-21 | Synthon B.V. | Process for making melflufen or a salt thereof |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| WO2023281007A1 (en) | 2021-07-08 | 2023-01-12 | Oncopeptides Ab | Melflufen for use in the treatment of multiple myeloma |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
| WO2026057823A1 (en) * | 2024-09-13 | 2026-03-19 | Oncopeptides Ab | Bis-chloroethylamino derivatives for treating leukemia |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| WO2010044981A2 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2801061A1 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CA3024230C (en) * | 2011-04-28 | 2022-10-18 | Oncopeptides Ab | Lyophilized preparation of cytotoxic dipeptides |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| WO2014065751A1 (en) * | 2012-10-26 | 2014-05-01 | Oncopeptides Ab | Lyophilized preparations of melphalan flufenamide |
| EA202091397A1 (ru) | 2013-01-31 | 2020-09-04 | Ауспекс Фармацетикалс, Инк. | Бензохинолоновые ингибиторы vmat2 |
| KR20150115807A (ko) * | 2013-02-05 | 2015-10-14 | 임파 악치엔게젤샤프트 | 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제 |
| EA201791466A1 (ru) | 2013-12-03 | 2017-11-30 | Оспекс Фармасьютикалз, Инк. | Способы получения соединений бензохинолина |
| CN110229159B (zh) * | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| HRP20221106T1 (hr) | 2015-03-06 | 2022-11-25 | Auspex Pharmaceuticals, Inc. | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta |
| GB201507903D0 (en) * | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
-
2019
- 2019-10-17 PL PL19790194.5T patent/PL3866931T3/pl unknown
- 2019-10-17 AU AU2019362389A patent/AU2019362389B2/en active Active
- 2019-10-17 BR BR112021007060-5A patent/BR112021007060A2/pt unknown
- 2019-10-17 WO PCT/EP2019/078250 patent/WO2020079165A1/en not_active Ceased
- 2019-10-17 HU HUE19790194A patent/HUE061801T2/hu unknown
- 2019-10-17 KR KR1020217011490A patent/KR102848971B1/ko active Active
- 2019-10-17 EP EP19790194.5A patent/EP3866931B1/en active Active
- 2019-10-17 JP JP2021521145A patent/JP7603199B2/ja active Active
- 2019-10-17 CA CA3116198A patent/CA3116198A1/en active Pending
- 2019-10-17 MX MX2021004474A patent/MX2021004474A/es unknown
- 2019-10-17 FI FIEP19790194.5T patent/FI3866931T3/fi active
- 2019-10-17 SG SG11202103726RA patent/SG11202103726RA/en unknown
- 2019-10-17 CN CN201980068384.1A patent/CN112930214B/zh active Active
- 2019-10-17 ES ES19790194T patent/ES2942468T3/es active Active
- 2019-10-17 IL IL282231A patent/IL282231B2/en unknown
- 2019-10-17 US US17/286,002 patent/US12152087B2/en active Active
- 2019-10-17 DK DK19790194.5T patent/DK3866931T3/da active
- 2019-10-17 MA MA053904A patent/MA53904A/fr unknown
-
2021
- 2021-04-15 ZA ZA2021/02492A patent/ZA202102492B/en unknown
-
2024
- 2024-07-03 JP JP2024107578A patent/JP2024150488A/ja active Pending
- 2024-10-16 US US18/917,773 patent/US20250115637A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210388024A1 (en) | 2021-12-16 |
| ZA202102492B (en) | 2024-04-24 |
| JP2022512736A (ja) | 2022-02-07 |
| US20250115637A1 (en) | 2025-04-10 |
| JP2024150488A (ja) | 2024-10-23 |
| DK3866931T3 (da) | 2023-04-24 |
| IL282231A (en) | 2021-05-31 |
| KR20210078487A (ko) | 2021-06-28 |
| PL3866931T3 (pl) | 2023-06-19 |
| WO2020079165A1 (en) | 2020-04-23 |
| ES2942468T3 (es) | 2023-06-01 |
| AU2019362389B2 (en) | 2024-12-12 |
| KR102848971B1 (ko) | 2025-08-21 |
| IL282231B2 (en) | 2025-07-01 |
| EP3866931B1 (en) | 2023-02-15 |
| MA53904A (fr) | 2021-08-25 |
| SG11202103726RA (en) | 2021-05-28 |
| BR112021007060A2 (pt) | 2021-07-20 |
| FI3866931T3 (fi) | 2023-05-10 |
| HUE061801T2 (hu) | 2023-08-28 |
| CN112930214A (zh) | 2021-06-08 |
| CN112930214B (zh) | 2025-05-16 |
| EP3866931A1 (en) | 2021-08-25 |
| US12152087B2 (en) | 2024-11-26 |
| IL282231B1 (en) | 2025-03-01 |
| JP7603199B2 (ja) | 2024-12-20 |
| MX2021004474A (es) | 2021-08-24 |
| AU2019362389A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3866931B1 (en) | Compounds containing deuterium | |
| KR101612642B1 (ko) | 테노포비어 알라펜아미드 헤미푸마레이트 | |
| KR101125932B1 (ko) | (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태 | |
| EP3805237B1 (en) | Synthesis and uses of peptide borate ester compound | |
| US12558337B2 (en) | Formulations comprising melflufen | |
| JP2018509441A (ja) | 水溶性プロドラッグ | |
| CN102731510B (zh) | 替卡格雷的衍生物、制备方法及其药物用途 | |
| CZ159197A3 (cs) | Inhibitory metalloproteinázy, způsob jejich výroby a farmaceutický prostředek s jejich obsahem | |
| KR102750784B1 (ko) | 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 제조방법 및 그 중간체 | |
| CA2070983A1 (en) | Cyclic renin inhibitors | |
| HK40048606B (en) | Compounds containing deuterium | |
| HK40048606A (en) | Compounds containing deuterium | |
| CN120774918A (zh) | 蛋白降解剂类化合物及其制备方法、药物组合物和应用 | |
| US9217001B2 (en) | Crystalline bortezomib process | |
| EA045396B1 (ru) | Соединения, содержащие дейтерий | |
| JPH06172287A (ja) | アミノカルボン酸誘導体及び該化合物を含有する医薬組成物 | |
| EP3081556A1 (en) | Amide compound and pharmaceutical comprising same | |
| WO2020046941A1 (en) | Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same | |
| HK40047998A (en) | Nitroxoline prodrug and use thereof | |
| WO2009012656A1 (en) | Inhibitors for matrix metalloproteinases, pharmaceutical compositions containing them and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240925 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240925 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240925 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241001 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241120 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250422 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251124 |